Skip to content Skip to footer

Research Portal of the TU Dresden

CNS Drugs

ISSNs: 1172-7047

Additional searchable ISSN (electronic): 1179-1934

Adis International Ltd

Scopus rating (2023): CiteScore 12 SJR 1.616 SNIP 1.809

Journal

Titles	CNS Drugs CNS drugs
Additional searchable titles	CNS drugs, CNS drugs.
ISSNs	1172-7047
Additional searchable ISSN (electronic)	1179-1934
Publisher	Adis International Ltd
ZDB-ID	1203800-3
ZDB-ID	2043806-0

Keywords

ASJC Scopus subject areas

Library keywords

610 Medicine and health

Related content

Research output

Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis

Jiang, T., Ziemssen, T., Wray, S., Shen, C., Söderbärg, K., Lewin, J. B., Božin, I., & 1 othersFreedman, M. S., May 2023, In: CNS drugs. 37, 5, p. 441-452 12 p.

Research output: Contribution to journal › Research article › Contributed › peer-review

Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study

Ludwig, V. M., Sauer, C., Young, A. H., Rucker, J., Bauer, M., Findeis, H. & Ritter, P., Aug 2021, In: CNS drugs. 35, 8, p. 881-892 12 p.

Research output: Contribution to journal › Research article › Contributed › peer-review

Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study

Ziemssen, T., Bass, A. D., Berkovich, R., Comi, G., Eichau, S., Hobart, J., Hunter, S. F., & 12 othersLaGanke, C., Limmroth, V., Pelletier, D., Pozzilli, C., Schippling, S., Sousa, L., Traboulsee, A., Uitdehaag, B. M. J., Wijmeersch, B. V., Choudhry, Z., Daizadeh, N. & Singer, B. A., 24 Sept 2020, In: CNS drugs.

Research output: Contribution to journal › Research article › Contributed › peer-review

Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study

EVOLVE-MS-2 Study Group, Feb 2020, In: CNS drugs. 34, 2, p. 185-196 12 p.

Research output: Contribution to journal › Research article › Contributed › peer-review

Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine

Hobart, J., Ziemssen, T., Feys, P., Linnebank, M., Goodman, A. D., Farrell, R., Hupperts, R., & 6 othersBlight, A. R., Englishby, V., McNeill, M., Chang, I., Lima, G. & Elkins, J., 2019, In: CNS drugs.

Research output: Contribution to journal › Research article › Contributed › peer-review

View all research output (7)